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                              SUMMARY 
1. A protein that potentiates the action of insulin in vitro 
was purified from human plasma by a procedure involving Sephadex 
G-100 column chromatography and reversed-phase HPLC. The 
purified material gave a single band with an apparent molecular 
weight of 16,000 on SDS-polyacrylamide gel electrophoresis. 
When reduced with 2-mercaptoethanol and then carboxymethylated, 
it also gave only a single band, but with a lower molecular 
weight than that of the unreduced material. By gel filtration 
chromatography on Sephadex G-75 in 6 M guanidine hydrochloride, 
the molecular weight of the unreduced material was estimated as 
17,000 and that of the reduced material as 9,000, indicating that 
it was composed of two polypeptide chains of equal or nearly 
equal molecular weight connected by one or more disulfied bonds. 
The modified subunit tended to inhibit rather than stimulate 
insulin activity. 
2. A distinctive feature of the amino acid composition of 
this protein (H-ISP) was the absence of histidine, arginine, and 
tryptophan. The N-terminal amino acid residue of H-ISP was 
pyrrolidone carboxylic acid. The molecular  weight,  'subunit 
composition, the characteristic amino acid composition and the N-
terminal amino acid residue of H-ISP are very similar to those of 
human plasma apolipoprotein  A-II (apo  A-II), one of the two major 
apolipoprotein components of human plasma high density 
lipoproteins. The isoelectric point of H-ISP was estimated to 
be 4.91, which is identical with that of the major apo  A-II 
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   isoform. 
  3. H-ISP did not itself have insulin-like activity in 
  increasing CO2 liberation from labeled glucose, lipid synthesis,
  and 2-deoxyglucose uptake by isolated rat adipocytes, but it 
  potentiated the action of insulin in these parameters. It had 
  no appreciable affect on the binding or degradation of 125I-
  labeled insulin by adipocytes. Like H-ISP, apo  A-II isolated 
  from human plasma also had no insulin-like activity by itself, 
  but stimulated the effect of insulin on CO2 production from 
   labeled glucose in isolated rat adipocytes. From these results, 
  it is concluded that H-ISP is identical with the major apo  A-II 
   isoform. 
  4. Incubation of isolated adipocytes with H-ISP resulted in 
  marked increase in the activity of pyruvate dehydrogenase in a 
   dose-dependent manner in the absence of added insulin. H-ISP 
  also stimulated pyruvate dehydrogenase activity in a subcellular 
   system consisting of plasma membranes and mitochondria from rat 
  adipocytes. The effect of H-ISP on pyruvate dehydrogenase 
  activity could be produced by treatment of the isolated 
   mitochondrial fraction alone. Sodium fluoride, an inhibitor of 
   phosphatase, blocked the action of H-ISP almost completely, 
   suggesting that the stimulatory effect of H-ISP on pyruvate 
  dehydrogenase activity is at least partly due to its activation 
   of pyruvate dehydrogenase phosphatase. 
   5. We studied whether the insulin-potentiating action of H-
   ISP is related to a modification of the insulin receptor kinase. 
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In a solubilized rat adipocyte receptor system, H-ISP caused 
dose-dependent inhibition of the stimulation by insulin of 
phosphorylation of the 95,000 dalton subunit of insulin receptor. 
During the phosphorylation reaction, no phosphorylated forms of 
the protein could be detected. H-ISP had no effect on 
dephosphorylation of the phosphorylated  Is subunit of the insulin 
receptor. These results strongly suggest that the inhibition of 
phosphorylation by H-ISP is due not to either simple substrate 
competition or activation of phosphoprotein phosphatase, but to 
specific inhibition of tyrosine-specific protein kinase. 
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                            INTRODUCTION 
     Since the discovery of insulin over 60 years ago, many 
investigators have devoted considerable effort in attempting to 
unravel the mechanism of action of this hormone. This is not 
only the result of the utility of this hormone as a model system 
for peptide hormone action, but also a reflection of the 
importance of insulin in human biology and medicine (1,2). 
Whereas deficiencies of most peptide hormones lead to relatively 
mild or moderate disease states, total lack of insulin is 
incompatible with life. In addition, diabetes mellitus and 
other disorders of carbohydrate metabolism characterized by 
abnormalities in insulin  secretion  or insulin action are among 
common metabolic diseases. Thus, a clear biochemical 
understanding of the mechanism of insulin action is of utmost 
importance. 
     It is well accepted that the action of insulin is greatly 
influenced by alterations in sensitivity or responsiveness of 
target tissues to the hormone (1,2). However, little is known 
about the mechanisms of these phenomena. In 1929, Glaser and 
Halpern (3) reported that yeast extract contains a factor(s) that 
potentiates the hypoglycemic action of insulin in vivo. This 
interesting observation was, however, not followed up and hence 
the nature of the factor and even its existence are still 
unknown. It has also been reported from different laboratories 
that a pentapeptide from the carboxyl-terminal of the insulin B-
chain (B22-26) (4,5), a hexapeptide from the amino-terminal 
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sequence of human growth hormone (hGH 8-16) (6)  potentiate the 
action of insulin in vitro when added at rather high 
concentrations. Recently, we tried to purify the insulin-
stimulating factor from brewer's yeast and clarify its action. 
During this study, we incidentally found that limited proteolysis 
of bovine serum albumin with trypsin produced an insulin-
stimulating peptide that was functionally similar to that in 
yeast extract and we  determined the structure of this peptide 
(7-9). These findings suggest the presence of a substance(s) 
that  controls the action of insulin in vivo. Furthermore,  Arner 
et al. (10) and Livingston et al. (11) demonstrated a marked 
increase in the insulin sensitivity of human and rat fat cells 
after carbohydrate challenge and suggested the existence of some 
physiological process causing rapid increase in the effect of 
insulin. 
     An insulin-stimulating peptide (ISP) isolated from a tryptic 
digest of bovine serum albumin has the following characteristics: 
1)  ISP is a two-chain polypeptide consisting 71 amino acid 
residues (calculated Mr=8,496), corresponding essentially to 
residues 115-143 and 144-184(185) of bovine serum albumin 
connected to each other by a disulfied bond. The linkage of the 
subunits through a disulfied bond is essential for manifestation 
of its action. 2)  ISP potentiates the effects of insulin on 
glucose transport and glucose metabolism in isolated rat 
adipocytes. It shifts the concentration-response curve of 
insulin-stimulated  D-[1-14C]glucose oxidation, 2-deoxyglucose 
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transport, and lipid synthesis from  D-  [u_14c]  glucose to lower 
insulin concentrations, but it has little effect alone. It also 
increases the maximal response of these parameters to insulin. 
3)  ISP has no appreciable effect on specific binding of insulin 
to adipocytes, and effectively protects insulin from degradation. 
These findings indicate that ISP may be useful in studies on the 
mechanisms of insulin action including both the sensitivities and 
responsiveness of target cells to the hormone. Subsequently, we 
found that a protein with the ability to potentiate the action 
of insulin in vitro is present in human plasma and we isolated 
this protein from human plasma (12,13). Like ISP, this protein 
(H-ISP) did not itself have insulin-like activity, but enhanced 
the action of insulin on fatty acid synthesis from glucose in rat 
adipose tissue explants and on CO2 production from glucose in 
isolated rat adipocytes. The present paper reports further 
characterization of this protein, including its primary 
structure. 
     The events that follow the binding of insulin to its 
receptor on the plasma membrane of target cells and that mediate 
the intracellular effects of the hormone have long been the 
subject of speculation and investigation but remain largely 
unknown. A major hindrance to solving this problem has been the 
lack of an adequate in vitro model system for studying the 
mechanism of insulin action. Recently however, it has been 
demonstrated that a simplified subcellular system consisting of 
plasma membranes and mitochondrial fractions from rat adipocytes 
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could be used as a model system for studying the action of 
insulin (14-16). A number of recent studies have indicated that 
the interaction of insulin with its receptor on the plasma 
membrane of target cells results in the generation of a 
"putative" insulin mediator(s) that modulates the activities of 
various insulin-sensitive enzymes. These enzymes include 
pyruvate dehydrogenase (14-17), cAMP-dependent protein kinase 
(18), glycogen synthase (18),  acety-CoA carboxylase (19), 
adenylate cyclase (20), low-Km phosphodiesterase (21,22) and 
 Ca++,  Mg" ATPase (23). However, the exact chemical nature and 
biological significance of the mediator(s) are poorly understood. 
In the present study, we showed that an  insulin-stimulating 
protein from human plasma potentiates the activity of pyruvate 
dehydrogenase in intact cells and in subcellular systems in the 
absence of added insulin. 
     Insulin receptor is an integral membrane glycoprotein 
composed of two  a subunits (Mr 135,000) and two  e, subunits (Mr 
95,000) linked by disulfied bonds (24,25). Covalent cross-
linking of to the receptor suggests that the 
a subunit is the insulin-binding subunit (24-26). The  f3 subunit 
appears to be a transmembrane protein which contains a binding 
site for ATP  (27). Recent in vitro studies have demonstrated 
that insulin binding to the receptor stimulates tyrosine 
autophosphorylation of the  a subunit of this receptor both in 
intact cells and in solubilized receptor preparations (28-30) and 
that the insulin receptor itself functions as a tyrosine-specific 
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protein kinase (29,30). It is believed that insulin-stimulated 
 autopho  sphorylati  on of the receptor kinase is the first 
postbinding event in insulin signal transmission across the 
plasma membrane. 
     In the present study, the first part deals with 1) 
purification of an insulin-stimulating protein from human plasma, 
2) amino acid sequence of this protein. In the second part, 
biological activities of this protein, including the mechanism of 
action of this protein, were investigated. We also studied the 
effect of this protein on the phosphorylation of rat adipocyte 
insulin receptor to determine whether the potentiation of 
insulin-stimulated glucose metabolism by this protein is 
correlated with alteration of the tyrosine protein kinase 
activity of the insulin receptor. 
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                      MATERIALS AND METHODS 
Materials  
    The following materials were purchased; crystalline porcine 
insulin (25.9 U/mg), bovine albumin essentially free from fatty 
acid globulin, thiamine pyrophosphate,  (i-NAD,  CoA, aprotinin, and 
pyruvic acid (sodium salt) from Sigma Chemical; collagenase Type 
1 (Clostridium histolyticum) and TPCK-treated trypsin from 
Cooper Biomedical; ampholine, pH 4-6, from LKB; ATP  (disodium' 
 salt), dithiothreitol, and pyrrolidonecarboxylate peptidase from 
Boehringer Mannheim GmbH; carboxypeptidase Y from Oriental Yeast 
Co. (Tokyo); Staphyolcoccus aureus V8 protease and wheat germ 
agglutinin coupled agarose from Miles Laboratories; 
aminopeptidase M from Pierce Chemical Co,; sodium fluoride,  p-
                            , APMSF, and Triton X-100 from Wako Pure Chemical Industries, Ltd. 
(Osaka); N-acetyl-D-glucosamine and TLCK from Nakarai Chemicals, 
Ltd.  (Kyoto); leupeptin from the Peptide Institute, Inc. 
 (Osaka); Pansorbin from Carbiochem;  D-[1_14c]glucose,  D-  [U-
14C]glucose
, and 2-deoxy-D-[1-3H]glucose from the Radiochemical 
Centre;  [  1-32NATP from ICN;  [  1_14c]  pyruvic acid and porcine 
 125I-insulin (2 .2 Ci/pmol, receptor grade) from New England 
Nuclear. Human apo  A-II was prepared by Mr. Tsutomu Uenoyama, 
Department of Research and Development, Otsuka Pharmaceutical 
Factory, Inc., Tokushima, by the methods of Burstein et al. (31) 
and Scanu et al. (32). All other reagents were standard 
products of the highest grade available commercially. 
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Amino acid analysis  
     For determination of the amino acid composition of H-ISP, 
                                                              110°samples were hydrolyzed in 4 M methanesulfonic acid at C for
24, 48 and 72 h in evacuated sealed tubes (33). For 
determination of the amino acid compositions of proteolytic 
peptides of H-ISP, about 3-6 nmoles of peptides were hydrolyzed 
under the same conditions but for 24 h. The half-cystine content 
was determined as S-carboxymethylcysteine (34). All analyses 
were carried out in a Hitachi 835 amino acid analyzer. 
Modification reactions  
     Reduction and carboxymethylation of H-ISP was carried out 
essentially as described by Crestfield et al. (35).  'H-ISP (2 mg) 
was reduced with 2-mercaptoethanol (60 pmol) in 3 ml of 0.36 M 
Tris-HC1/8 M urea/0.2 % Na2EDTA, pH 8.0, for 4 h at 25°C. and 
subsequently S-carboxymethylated with iodoacetic acid (58  pmol) 
for 15  min at  25°C. The reaction mixture was applied directly to 
a Sephadex G-75 column (2.2 X 45 cm) that had been equilibrated 
with 0.5 N acetic acid and wrapped in aluminium foil. The S-
carboxymethylated  H-ISP was purified by chromatography on a Hi-
Pore RP-304 reversed-phase HPLC column. 
Edman-degradation  
     Reduced and carboxymethylated H-ISP (Cm-H-ISP) was degraded 
manually by the Edman method (36) and the resulting  3-pheny1-2- 
thiohydantoin derivatives of amino acids were analyzed as 
described by Shimonishi et al.  (37). 
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           Enzymatic digestion  
                 Cm-H-ISP (about 25 nmol) was divided into two portions. One 
           portion was digested with TPCK-treated trypsin in 0.5 % ammonium 
           bicarbonate (pH 8.0) at 37°C for 4 h at a substrate:enzyme ratio 
           of 50:1 to 100:1. One quarter of the digest was used for FAB 
           mass spectrometry and the remainder was separated by HPLC.
            Another portion of Cm-H-ISP was treated with V8 enzyme in 0.5 %
           ammonium bicarbonate (pH 8.0) at 37°C for 16 h at a sub= 
           strate:enzyme ratio of 50:1. Two-fifths of the digest was used 
          for mass spectrometry, and three-fifths for HPLC. 
           Carboxypeptidase Y and aminopeptidase M digestions were carried
           out in 0.1 M pyridinium acetate at 37°C and pH  6.0'for 1.5 h and 
           at 37°C and pH 7.0 for 1 h, respectively. Pyrrolidonecarboxylate 
           peptidase digestion was done as described by Tsuru et al (38). 
           High-performance liquid chromatography (HPLC)  
                 The HPLC apparatus consisted as a Shimadzu HPLC apparatus 
           (Kyoto) fitted with a solvent programmer (GRE-2B) and a data 
           processor chromatopac C-RIA. The tryptic or V8 peptides 
           dissolved in 5 % acetonitrile containing 0.1 % trifluoroacetic 
           acid (pH 2.35) were injected into a reversed-phase column (4 X 
           250 mm) packed with YMC-ODS S-5 (Yamamura Chemical Laboratory 
           Co., Kyoto) equilibrated with the same solvent. Materials were 
           developed with the same solvent for 5  min and then with a  linear-
           gradient of 5-75 % acetonitrile in 0.1 % trifluoroacetic acid at 
           room temperature for 70  min at a flow rate of 1  ml/min. 
                For purification of H-ISP, a Waters ALC/GPC model 206D liquid 
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   chromatography system was used with an autogradient set (M-680 
   autogradient control and two M510 pumps). 
   Fast atom bombardment (FAB) mass spectrometry  
         FAB mass spectra were recorded with a Jeol double-focusing 
   mass spectrometer HX100 equipped with an FAB ion source and a 
   data processor (Jeol JMA-3100 mass data analysis system), as 
   described by Takao et al. (39). Typical experimental conditions
   were carried out with a xenon atom beam source at 7-KeV 
   accelating potential. Mass assignment was made using a mixture 
   of CsI and KI as a mass reference. A sample solution containing 
 1-10 pg of peptides was loaded on a stainless steel plate and 
   mixed with glycerol and a -thioglycerol on the plate. 
   Polyacrylamide gel electrophoresis  
        The modified Laemmli system of Ito et al. (40) was used, 
   except that the final acrylamide/bisacrylamide concentrations 
   were 20.86/0.096 %. Samples were dissolved in Laemmli's sample 
   buffer (41) and boiled for 3  min in the presence or absence of  2- 
   mercaptoethanol before application to the gels. The size of gel 
   slab was 150 (height) X 135 (width) X 1 (thickness) mm. 
         Electrophoresis was carried out at room temperature and at 
   15 mA for 5 h. The gel was subjected to staining overnight with
   0.25 % Coomasie brilliant blue R-250 containing 45.5 % methanol 
   and 9.2 % acetic acid, followed by washing with a mixture of 25.5 
   % ethanol and 8.2 % acetic acid. The gel thus washed was stored 
   in 5 % methanol containing 7.5 % acetic acid. The stained gel 
   slab was enveloped by a sheet of well wet cellophane, then 
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sandwiched by two sheets of porous plastic plate in a slab gel 
dryer. The dring was carried out at 50°C for 3 h under vacuum. 
     The molecular weight markers used were soybean trypsin 
inhibitor (Mr 20,500, Pharmacia) and the cyanogen bromide 
cleavage products of myoglobin (Mr 2,512 and 14,414, LKB). 
Isoelectric focusing  
     For gel electrophoresis, samples were dissolved in a buffer 
containing 8 M urea,  3  % ampholytes (pH range 4-6), 2  % 
dithiothreitol (w/v), and 10 % glycerol  (v/v). Analytical iso= 
electrophoresis was performed by the method of Lackner et al. 
 (42), in 5 X 130 mm gels containing 8 M urea, 7.5 % acrylamide,
and 7.5 % ampholytes (pH range 4-6). Electrophoresis was carried 
out for 18 h at 250 v at 4°C. The gels were sliced into 5 mm 
segments and each segment was extracted with 1 ml of water for 
determination of the pH. Protein bands were stained with 
Coomassie brilliant blue R-250. 
Gel filtration chromatography on Sephadex G-75 in 6  M guanidine  
hydrochloride  
     H-ISP and Cm-H-ISP were dissolved in 6  M guanidine 
hydrochloride, pH 5.0, and subjected to gel filtration through a 
Sephadex G-75 column (0.9 X 186 cm) equilibrated in 6 M guanidine 
hydrochloride at a constant flow rate of 10 ml  / h, and fractions 
of 1 ml were collected. The void volume was determined with blue 
dextran (Pharmacia). Molecular weight markers were myoglobin (Mr 
17,000, Sigma), oxidized bovine pancreatic  ribonuc  I  ease A (Mr 
13,000 Sigma), lima bean trypsin inhibitor (Mr 8,400 Cooper 
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Biomedical) and bovine pancreatic insulin (Mr 5,700, Sigma). 
Fatty acid synthesis in adipose tissue explants  
     For fatty acid synthesis, ten explants (total wet weight,  8-
10 mg) were prepared from epididymal fat pads of male Wister 
strain rats, weighing about 200 g, fed ad libitum. The explants 
were cultured on siliconized lens paper (43) in a sterile petri 
dish containing 3  ml of medium 199 supplemented with 0.05  }lCi/ml 
of  [U-14C] glucose, 1.5  mg/ml of NaHCO3 and antibiotics. After 
incubation for 20 h at  37°C under 3 % CO2 in air, unless 
otherwise specified, the explants were weighed and hydrolyzed in 
1 ml of 2 N KOH in 50 % ethanol for 2 h at  100°C. Fatty acids 
were extracted from the acidic hydrolyzate with 3  ml'of petroleum 
ether (44). This assay method was used for the purification of 
H-ISP. The explants, though less sensitive to insulin than 
isolated adipocytes, were easily prepared and responded to 
insulin in a dose-dependent manner. In addition,this method had 
the advantage that 50 assays could be made at the same time, 
thereby avoiding variations between assays. Under the conditions 
for this method, conversion of labeled glucose to fatty acids 
proceeded linearly with time in the presence of 20  mU/m1 of 
insulin for at least 22 h, while insulin at 0.2  mU/m1 caused 
little, if any (Fig.15). 
Preparation of isolated rat adipocytes  
     Epididymal fat pads were exised from male Wister rats 
weighing 120 to 150 g, which had been fed ad libitum. White fat 
cells were isolated from the fat pads by collagenase digestion as 
                              14
described by Rodbell (45).  Up to 1 g of adipose tissue was 
added to a polyethylene beaker containing 5 ml of Krebs-Ringer 
phosphate buffer supplemented with 10 mM Hepes, pH 7.4, 2.5 mg of 
collagenase, and 0.55 mM glucose. Incubation was carried out 
for 60  min at 37 C. The suspension of cells was centrifuged in 
polyethylene centrifuge tube for 1  min at 400 X g and the 
infranatant was removed. The fat cells were washed by suspending 
them in 10 ml of Krebs-Ringer phosphate Hepes buffer 
containing the desired concentration of glucose and centrifuged 
for 1  min at 400 X g. This procedure was repeated five times. 
Glucose oxidation  
     Conversion of D-[1-14C]glucose to  14CO2 by adipocytes was 
measured essentially as described by Fain et al. (46). Reaction 
mixtures contained fat cells (5-9 X  105 cells/ml),  D-[1- 
14C]glucose (0.2 mM, 0.3  pCi/ml), and 10 mg/ml of bovine serum 
albumin in a total volume of 0.4 ml of Krebs-Ringer phosphate 
Hepes buffer, pH 7.4.  14CO2 was collected and counted as 
described  (47). 
Lipid synthesis  
     The incorporation of  D-[U-14C]glucose (0.2  mM; specific 
activity, 2.5 pCi/pmol) into total lipids was measured after a 
similar incubation as for assay of glucose oxidation. The 
reaction was stopped by addition of 40  Fl of 6 N  H2SO4, and the 
medium containing adipocytes was then extracted by Dole's 
procedure (48). Aliquots were taken from the heptane layer for 
counting. 
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Glucose transport  
     Glucose transport activity was  assayed by measuring the 
uptake of 2-deoxy-D-[1-3H]glucose as described by Maloff and 
Lockwood (49). Adipocytes (5-7 X  105 cells/ml) in 0.4 ml of 
Krebs-Ringer phosphate Hepes buffer, pH 7.4, containing 10  mg/ml 
of bovine serum albumin were preincubated at 37°C for 1 h with or 
without H-ISP in the presence of insulin. The reaction was 
started by the addition of 2-deoxy-D-[1-3H]glucose (final 
concentration, 0.125 mM; specific activity, 15 mCi/mmol). The 
incubation was continued for 60 sec and terminated by rapid 
centrifugation through a layer of dinonyl phthalate (50). 
Insulin binding  
     Binding of  125I-labeled insulin to isolated adipocytes was 
assayed by the methos of Kikuchi et al. (51). Adipocytes (9 X 
105  cells/mil) in 0.4  ml  of Krebs-Ringer phosphate Hepes buffer, 
pH 7.4, containing 10  mg/ml of bovine serum albumin and 0.55  mM 
glucose were preincubated at 37°C for 1 h with of without H-ISP. 
Then they were rapidly cooled to 25°C and incubated at this 
temperature for 30  min with  125I-labeled insulin (final concent= 
ration, 70  pM; specific activity of insulin, 2.2 Ci/pmol) in the 
presence of various concentrations (0.03 to 100 nM) of native 
insulin. The reaction mixture was then subjected to rapid oil 
centrifugation (50). Specific binding was determined as the 
difference between total binding of labeled hormone and remaining 
binding in the presence of a large excess (58  yg/m1) of unlabeled 
hormone. 
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               Degradation of  125I-labeled insulin by isolated rat adipo= 
         cytes was assayed by measuring the radioactivity precipitated
         with 10  %  trichloroacetic acid, as described by Gammeltoft and 
         Gliemann (52), and by radioimmunoassay (53) after removal of
         cells by oil centrifugation. 
         Pyruvate dehydrogenase activity in isolated adipocytes  
               Pyruvate dehydrogenase activity of intact adipocytes was 
         measured essentially as described by Jarett et al. (54). Adipo=
         cytes (7-9 X  105  cells/ml) were incubated for 15  min at 37°C in a 
         total volume of 400  Fl of Krebs-Ringer phosphate buffer con=
 taining 10 mM  NaHCO3, 10  mM Hepes, 0.2 mM  glucose,'  and 10  mg/ml 
         of bovine serum albumin with H-ISP in the presence or absence of 
         insulin. The cell suspension was centrifuged and the infra=
         natant was discarded. The cell layer was washed once with 500 
 Fl of Krebs-Ringer phosphate buffer containing 10 mM  NaHCO3, 10 
 mM Hepes and recentrifuged. The infranatant was discarded and 
         the cell layer was extracted with 500  p1 of ice-cold solution of
         50  mM potassium phosphate buffer (pH 7.4), containing 0.2 % 
         Triton X-100, and 2 mM dithiothreitol,and vortexed for 30 sec . 
         The extract was recentrifuged, and chilled, and the lipid-free 
         infranatant was used for assay of pyruvate dehydrogenase 
         activity. Pyruvate dehydrogenase activity was assayed by 
         measuring release of  14CO2 from  [1-14C]pyruvic acid . The assay 
         was begun by the addition of assay mixture to give final concen= 
        trations of 50  mM potassium phosphate buffer (pH 7.4), 50 FM 
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 CaC12, 50  ,pM MgC12, 1 mM dithiothreitol, 0.1 mM  CoA, 0.1 mM 
thiamine pyrophosphate, 0.25  mM [1-14C]pyruvate (1  pCi/pmol), and 
0.5 mM After incubation for 3  min at 37°C, the reaction 
was stopped by adding 200 pl of 6 N  H2SO4.  14CO2 was collected 
and counted as described (47). 
Subcellular fractionation of adipocytes  
      Plasma membranes and mitochondria were prepared from adipo= 
cytes (from 16-24 rats) as described by Mckeel and Jarett (55). 
The isolated fat cells were washed once with 10 volumes of 
homogenization medium (medium I: 10 mM  Tris-HC1, pH 7.4, 1 mM 
EDTA, and 0.25  M sucrose) to rid the cells of the Krebs-Ringer 
phosphate buffer. The cells were resuspended  in'  at least 3.5 
volumes of medium I at room temperature and transferred to a 
glass homogenizer fitted with a Teflon pestle. Potter-Elvehjem 
glass homogenizers fitted with Teflon pestles were used to 
resuspend all subsequent pellets. The cell suspension was 
homogenized with 10 up-and-down strokes by means of a variable-
speed motor driven at 2600 rpm. The resulting homogenate was 
placed in ice, and all subsequent steps were carried out at 4°C. 
     The chilled homogenate was centrifuged at 16,000  X.g for 15 
 min, yielding a pellet, a supernatant solution, and a congealed 
fat cake. The pellet was resuspended in 8 ml of  medium I by six 
strokes at 1250 rpm and centrifuged at 1000 X g for 10  min. The 
supernatant was centrifuged at 17,000 X  g  for 20  min and the 
pellet was resuspended in 6 ml of medium I by 6 strokes at 1700 
rpm. The resulting suspension was further diluted with medium I 
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and placed on a continuous sucrose gradient. The gradients 
formed were 1.05 density at the top and 1.25 density at the 
bottom, and contained 1 mM EDTA and 5 mM Tris-HC1, pH 7.4. 
Centrifugation at 59,000 X g for 90  min resulted in the 
separation of two finely particulate bands at densities of 1.14 
and 1.18. The bands were removed separately and the 1.14 
density band was diluted 4:1 (v:v) with medium I. After being 
centrifugation at 16,000 X g for 15  min, the pellet was 
resuspended in 1-2 ml of a solution (medium II) that contained 
0.25 M sucrose and 10 mM Tris-HC1, pH 7.4. This was the plasma 
membrane fraction. Similarly, the 1.18 density band was 
removed, diluted 6:1 (v:v) with medium I and  centrifuged at 
16,000 X g for 15  min. The resulting pellet, resuspended in 1-2 
ml of medium II, constituted the mitochondrial fraction. The 
purity of these two fractions showed less than 10 % cross-
contamination. 
Pyruvate dehydrogenase activity in  subcellular systems  
     The plasma membranes (200  Fg/ml) and mitochondria (500 
 pg/ml) were preincubated for 10  min at  37 °Cin 200  Fl of 50  mM 
potassium phosphate buffer (pH 7.4) containing 50  FM CaC12, 50 FM 
 MgC12, and 250  FM ATP with insulin or H-ISP. The assay was 
begun by adding assay mixture as described above, and incubation 
was carried out for 3  min at 37°C. Pyruvate dehydrogenase 
activity was expressed per mg of mitochondrial protein in the 
sample per  min. Plasma membranes and mitochondrial fractions 
were generally used within 1-2 h after preparation. 
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       Preparation of a solubilized insulin receptor fraction  
             Insulin receptors were solubilized and purified by wheat 
       germ agglutinin affinity chromatography as described by  Hiring et 
       al. (56). Adipocytes (50 ml of a suspension of approximately 3 
 X  106  cells/ml) were washed four times with phosphate-free Krebs-
       Ringer phosphate Hepes buffer containing 0.5 % bovine serum 
       albumin, 12 mM  NaHCO3, and 0.55  mM glucose, and then immediately
       frozen. The cells were lysed by three cycles of freeze-thawing 
       in liquid nitrogen and a water bath, respectively, and the 
       resultant cell lysate was centrifuged for 90  min at 200,000 X g.
       The precipitate was dissolved in 25  mM Hepes, 1  %  Triton X-100, 2 
       mM p-APMSF, and aprotinin (1  U/ml) and centrifuged  for 60  min at
       the same speed as before. The supernatant (a solubilized 
       membranous fraction) was then applied to a column of wheat germ 
       agglutinin coupled to agarose and recycled five times through the 
       column. The column was washed extensively with 25 mM Hepes 
       buffer (pH 7.4) containing 0.1 % Triton X-100, and then bound 
       material was eluted in a final volume of 2 ml with buffer 
       supplemented with 0.3 M N-acetyl glucosamine and used as the 
       solubilized insulin receptor fraction within two days after 
       chromatography. 
       Phosphorylation and  dephosphorylation of insulin receptor  
            Partially purified insulin receptors were incubated with or 
       without insulin in the presence or absence of H-ISP at 25°C for 1
       h. Then the phosphorylation reaction was induced by incubating 
       the receptors with 5  FM [Y-32P1-ATP in 50 mM Hepes buffer, pH 
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7.4, containing 10 mM MgC12 and 2 mM MnC12 at 4°C for 60  min 
(56). The reaction was terminated by adding NaF (100 mM), 
sodium pyrophosphate (10  mM), EDTA (5  mM), and ATP (5  mM). 
Tyrosine-O-phosphorylated proteins containing the  f3 subunit of 
the insulin receptor were identified by immunoprecipitation with 
antibodies against phosphotyrosine (57). After 16 h at 4°C, 150 
pl of Protein A (Pansorbin; 10 % w/v)was added and incubation was 
continued for 1 h at 4°C. The precipitate was then collected by 
centrifugation at 10,000 X g for 5  min at 4°C and washd twice 
with RIPA buffer (58) and once with 1 % Triton and 0.1 % SDS. 
Immunoprecipitates were boiled for 3  min in Laemmli's sample 
buffer (41) in the presence or absence of  2-mer6aptoethanol. 
The solubilized samples were then analyzed by SDS/polyacrylamide 
gel electrophoresis with one of the following gel systems: 7.5 % 
acrylamide gel  (41), a 4-18 % linear gradient of acrylamide 
 (acrylamide  :  bis-acrylamide=  2  0  :  1)  , and 20.9 % acrylamide 
containing a trace amount of NaC1 (40). After electrophoresis, 
the slab gels were stained with Coomassie brilliant blue R250, 
destained, dried, and autoradiographed with Fuji RX film for 0.5 
to 2 days at  -70°C. 
    Dephosphorylation was studied by incubating the 
phosphorylated (for 15  min at 4°C), partially purified receptors 
in the presence of unlabeled ATP (1  mM) with or without H-ISP at 
4°C, as described by Tamura et al. (59). At suitable times the 
reaction was terminated by adding a solution of NaF, EDTA, 
 sodiumm pyrophosphate, and ATP at final concentrations of 100 mM, 
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         5 mM, 10 mM, and 25 mM, respectively. Immunoprecipitation, 
         SDS/polyacrilamide gel electrophoresis, and autoradiography were 
         then carried out as described above. 
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                               RESULTS  
A. Chemical characterization of an insulin-stimulating protein  
    (H-ISP) from human plasma  
A-I. Purification of H-ISP from human plasma  
     All purification steps are schematically shown in Fig. 1. 
                                Fig. 1 
Chilled ethanol (2 liters) was added to 1 liter of human plasma with 
stirring for 30  min in the cold. Insoluble material was removed by 
 centrifugation at 10,000 X g for 30  min, and the resulting supernatant 
was concentrated to about 300 ml at 37°C under reduced pressure. The 
concentrated supernatant was shaken with an equal volume of chloro= 
form, and the aqueous phase was concentrated to about 200 ml under 
reduced pressure, dialyzed overnight against two changes of distilled 
water (5 liters each) in a Spectrapor 3 (Spectrum Medical; 3500 Mr 
cutoff) and lyophilized. 
     The dried material (about 200 mg protein) was dissolved in 15 ml 
of 10  mM Tris-HC1 buffer containing 0.1  M NaC1 (pH 7.4) and passed 
through a Sephadex G-100 column (4.4 X 90 cm) in the same buffer at 
a flow rate of 20  ml/h. Fractions containing H-ISP activity were 
pooled, dialyzed, and lyophilized. 
                                Fig. 2
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         The lyophilized material was dissolved in distilled water and 
    fractinated on a TSK gel ODS-120A column (7.8 X 300 mm, Toyo Soda) 
   with 0.1% TFA (solvent A) as the mobile phase, and 90% acetonitrile 
    containing 0.1% TFA (solvent B) as a mobile-phase modifier. Elution 
    was carried out with a linear gradient of solvent B as follows: 
    53% B for 20  min, 53-66% B in 30  min and 66-100% B in 10 min at a 
    flow rate of 1  ml/min at 22-25°C. H-ISP activity was eluted from
    the column after 42 to 50  min under these conditions. 
 Fig.  3 
    Final purification was achieved on a Hi-Pore RP304 column (4.6 X 
    250 mm, Bio-Rad) with solvent A as the mobile phase, and solvent B 
    as the mobile-phase modifier. Elution was effected with a linear 
    gradient of solvent B as follows: 0-40% B in 5  min, 40-60% B in 
    40  min and 60-100% B in 5  min at a flow rate of 1  ml/min at 22-25°C 
    (Fig.  4). 
 Fig.  4 
    Purified H-ISP was stable on heating at 60°C for 10  min and no loss 
    of activity was observed on storage as an aqueous solution for at 
    least 6 months at -20°C or for 24 h at 4°C at pH 2.0. 
    Homogeneity and molecular weight of the purified H-ISP  
         As shown in Fig. 5, the purified material in the non-reduced 
    state gave only a single band with an apparent molecular weight of 
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    16,000 on SDS-polyacrylamide gel electrophoresis (lane 1). 
                                     Fig. 5 
    After reduction with 2-mercaptoethanol, the material also gave only 
    a single band, but with a lower molecular weight than that of the 
    unreduced material (lane 2). 
         By gel filtration chromatography on Sephadex G-75 in 6  M gua= 
    nidine hydrochloride, the molecular  weight  of H-ISP was estimated
    as 17,000 and that of the modified material (Cm-H-ISP) as 9,000 ( 
    Fig.  6). 
 Fig.  6 
   These findings suggest that H-ISP is composed of two polypeptide 
    chains of equal or nearly equal molecular weight connected by one or 
    more disulfide bonds. 
    Amino acid composition of H-ISP  
         The amino acid composition of H-ISP is shown in Table  1. 
                                  Table 1 
    A distinctive feature of the composition is the absence of histidine, 
    arginine, and tryptophan. Assuming that the molecular weight is 
    about 16,000, the results show that H-ISP contains two half-cystine
   residues, suggesting that it is composed of two polypeptide chains 
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    of equal molecular weight connected by a single disulfide bond. 
    The characteristic amino acid composition is similar to that of human 
    plasma apolipoprotein  A-II (apo  A-II) (60), one of the two major 
    apolipoprotein components of human plasma high density lipoproteins. 
         Apo  A-II is polymorphic in human plasma, and four isoforms have 
    been detected (42). Figure 7 shows the result of isoelectric gel
    focusing of H-ISP and apo  A-II. 
 Fig.  7 
    The isoelectric point  (pI) of H-ISP was estimated to be 4.91. Under 
    the  experimental conditions, apo  A-II was polymorphic. The  pI of the 
    major apo  A-II isoform was 4.91, while the  pI values of the minor 
    apo  A-II isoforms were 4.67, 4.79, 5.00, and 5.17, respectively.
    Thus the  pI of H-ISP was the same as that of the major apo  A-II iso= 
     form. 
         Although the amino acid composition of the apo  A-II used in this 
    study was identical with that reported for apo  A-II (60), the  pI 
    values of its minor apo  A-II isoforms were different from those 
    reported by Lackner et al. (42). It is not clear whether this 
    difference was due to small amounts of impurities in our sample or 
    due to the presence of some type of as yet unidentified form in human 
    plasma. To further confirm the identity of H-ISP with apo  A-II, 
    we examined the amino acid sequence of H-ISP. 
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 A-II. Amino acid sequence of H-ISP  
            For establishment of the amino acid sequence of H-ISP, Cm-H-ISP 
     was first submitted to Edman-degradation. However, no N-treminal 
     amino acid residue could be detected, suggesting that the N-terminus 
     of H-ISP is pyrrolidone carboxylic acid or is blocked by an acyl 
      group. 
            Then, Cm-H-ISP was digested with trypsin and a part of the 
     digest was separated by reversed-phase HPLC, as shown in Fig. 8. 
 Fig.  8 
     The remainder of the tryptic digest was examined directly by FAB mass 
     spectrometry (Fig. 9) as described by Takao et al. (39). 
 Fig.  9 
     From the observed amino acid ratios and mass values of the separated 
     peptides, the integer values of the amino acid contents of the 
     isolated peptides were determined to be as shown in Table 2 . 
                                    Table 2 
     T-2 was a mixture of two peptides. The major component (T-2A) 
     corresponded to the signal observed at m/z=635.4 and consisted of 
     5 amino acid residues, while the minor one (T-2B) corresponded to
     the signal at m/z=1199.6 and consisted of 11 amino acid residues . 
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                                                              2
 T-2B contained one Val and one Lys residue more than T-1 and it had 
 two Lys residues, presumably one of which was not cleaved by trypsin, 
 because the carboxyl-proximal residue is proline, as reported below. 
 T-4 had one Ser and one Lys residue more than T-5 and contained two 
 Lys residues, one of which could not be cleaved for the same reason 
 as that in T-2B. The recoveries of amino acids from T-4 and T-5 were 
 less than those from  T-1, T-2 and T-6, but their sum was almost the 
 same as that of the other three peptides. Therefore, T-4 and T-5 
 were concluded to originate from the same sequence. T-8 and T-9 both 
 corresponded to the signal at m/z=2385.3, because they had the same 
 amino acid compositions except for  Gln or Lys and their molecular 
 weights were approximately the same. T-8, T-9, and  T-10 contained 
 one  Gin, one Lys, and one  Gln and one Lys residue, respectively, less 
 than T-7. Since the recoveries of amino acids from T-7, T-8, T-9, 
 and  T-10 were all low and the amino acid composition of these peptides 
 were similar, we deduced that they were derived from the same sequence. 
 A signal observed  atm/z=2968.5 in Fig. 9 did not correspond to any 
 peptide isolated by HPLC in Fig. 8. However, this mass value coincided 
 with the sum of the mass values of T-2A and T-6, indicating that T-2A 
 and T-6 were consecutive peptides. 
        From amino acid analysis, Cm-H-ISP was deduced to contain a 
 total of 77 amino acid residues, including 9 Lys residues. On the 
 contrary, mass measurement of the tryptic peptides and amino acid 
 analyses  of the separated peptides indicated that it contained 74 
 amino acid residues with 8 Lys residues. Furthermore, mass measurement 
 indicated that N-termini of the peptides isolated by HPLC were not 
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 blocked. These results suggest that the N-terminal peptide of Cm-
 H-ISP was not detectable in the mass spectrum in Fig. 9 or by HPLC 
 in Fig. 8, and that it consisted of about 3 amino acid residues. 
       Then Cm-H-ISP was cleaved by S. aureus protease V8, and the V8 
 peptides were separated by HPLC (Fig. 10) or measured directly by FAB 
 mass spectrometry (Fig. 11). 
                                 Fig. 10
                                 Fig. 11
 The amino acid compositions of the separated peptides were determined , 
 as described in Table 3, from the observed amino acid ratios and mass 
 values as described for analyses of the tryptic peptides . 
                                Table 3 
 -Peptides  V-4 seemed to have a common sequence with peptide V-3
, because 
 it had the same amino acid composition as V-3 except for one less Gln 
 residue, and the recovery of V-4 was lower than those of other peptides , 
 but the sum of the recoveries of V-3 and V-4 was nearly equal to 
 those of other peptides. No signal with the mass value calculated 
 from the amino acid composition of V-5 could be detected in the mass 
 spectrum shown in Fig.  11. When isolated V-5 was submitted to FAB 
 mass spectrometry (Fig. 12), it gave a signal at m/z=944 .4, which 
 was 18 atomic mass units (amu) amaller than the mass value calculated 
                               29
from the observed amino acid composition. 
                                Fig. 12
Furthermore, the signal in the mass spectrum in Fig. 11 was at  m/z= 
944.7. Since 18 amu corresponds to the mass value of  H2O, the results 
suggest that the N-terminus of this peptide is a pyrrolidone  carboxy= 
lic acid (PCA). Moreover, when peptide V-5 was digested with  pyrro= 
lidonecarboxylate peptidase (38) and the digest was measured by FAB 
mass spectrometry (Fig. 12), the signal of the peptide at m/z=944.4 
disappeared and a new signal was observed at  m/z=833.3. The difference 
of these mass values was 111, which correspoded to the residual weight 
of PCA. These results indicated that V-5 has PCA at the N-terminus 
and therefore, that the peptide is located in the N-terminal position 
of Cm-H-ISP. 
     Comparison of the total amino acid composition of the tryptic 
and V8 peptides with that of Cm-H-ISP indicated that a peptide composed 
of one residue each of Glu, Ala, and Lys should present among the 
tryptic peptides, although it could not be detected from the mass 
spectrum (Fig. 9) or by HPLC (Fig. 8) of the tryptic peptides. 
The N-terminal amino acid residue of these amino acid residues in the 
peptide was considered to be PCA, because no blocked peptide was 
found among the tryptic peptides in Table 2 and a peptide (V-5) with 
PCA as an N-terminal residue was found among the V8 peptides. 
On the other hand, a peptide consisting of one Glu, one Ser, and two 
Lys residues should be present among the V8 peptides, because mass 
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measurments and amino acid analyses of the V8 peptides indicated the 
presence of 73 amino acid residues. A peptide containing these four 
amino acid residues could not be isolated by HPLC (Fig. 10), but it 
was detected as a signal at  m/z=491.3 in another mass spectrum 
not  shown). 
     These results were used as input data in a computer program 
developed and modified in our laboratory (61) and a candidate amino 
acid sequence of Cm-H-ISP was searched. The result is shown in 
Fig. 13. 
 Fig.  13 
The sequence was compatible with the overlaps of fragments  T-6/V-5, 
T-2A/V-8 and T-4 or T-5/V-7 with single residues of Cys, Met and  Ile, 
respectively. The partial sequence and amino acid composition thus 
determined were compared with the known amino acid sequences of 
plasma proteins. The sequence determined was very similar to that 
of human plasma apo  A-II (60). In fact, the amino acid compositions 
of the tryptic peptides were almost the same as those reported by 
Brewer et al. (60). To confirm the identity of our sequence with 
that of apo  A-II, we examined the partial sequence of the tryptic 
peptides isolated in Fig. 8. As an example, the FAB mass spectrum 
of the CPase digest of T-2 is shown in Fig. 14. 
                               Fig. 14 
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The result indicated that T-2B has Gln-Ala-Glu-Ala-Lys as its C-
terminal sequence. This sequence was identical with that from 35 
to 39 of apo  A-II (60) except at position 37; our sequence had a Glu 
residue instead of Gln at this position. Moreover, the FAB mass 
spectrum of an aminopeptidase digest of T-2 indicated that T-2B had 
Ser and Pro in its N-terminal portion, which were compatible with 
the sequence described by Brewer et al. (60). 
B. Biological activities of H-ISP  
B-I. Effect of H-ISP on fatty acid synthesis in adipose tissue explants 
     As shown in Fig. 15, the purified H-ISP greatly  stimulated the 
action of insulin added at a suboptimal concentration (0 .2  mU/m1) on 
fatty acid synthesis, the value being close to that obtained with 
20  mU/m1 of insulin alone. 
                                Fig. 15 
     Figure 16A shows the dose-response curve of H-ISP for fatty acid 
synthesis in the adipose tissue explant system . In the presence of 
0.2  mU/m1 of insulin, H-ISP was effective at over 2  pg/m1 of  H-ISP . 
H-ISP alone had no insulin-like activity in the concentration range 
tested. 
                             Fig. 16A 
• 
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Using the same system, the effect of H-ISP was tested as a function 
of the concentration of insulin. As shown in Fig. 16B, H-ISP shifted 
the concentration-resoense curve of insulin-stimulated fatty acid 
synthesis to the left. 
                               Fig. 16B 
 B-II. Effect of H-ISP on glucose oxidation, lipid synthesis from  
      glucose, and  2-deoxyglucose uptake by isolated rat adipocytes  
Effect of H-ISP on glucose oxidation  inthe presence and absence of  
insulin  
      As shown in Fig. 17, H-ISP also stimulated  14CO2 production 
from  D-[1-14C]glucose in the presence of insulin by isolated rat 
adipocytes. In the concentration range  tested,  H-ISP alone had no 
insulin-like activity measured as increase in  14CO2 production from 
labeled glucose, but at 0.1 to 3  11M H-ISP stimulated  14CO2 production 
from glucose in the presence of a submaximal concentration of insulin 
(67 pM) (Fig. 17A). 
                               Fig. 17A 
       Next, the effect of H-ISP was tested as a function of the 
concentration of insulin. As shown Fig. 17B, H-ISP at 1.2  mM shifted 
the insulin dose-response curve for  14CO2 production to the left, and 
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increased the maximal effect of insulin on glucose oxidation 
significantly  (40%). 
                               Fig. 17B 
      As shown in Table 4, when H-ISP was reduced with 2-mercapto= 
ethanol and then carboxymethylated with iodoacetic acid (Cm-H-ISP) 
it showed no insulin-stimulating activity, but rather inhibited the 
action of insulin. 
 Table  4 
Cm-H-ISP also exhibited no insulin-stimulating activity on fatty 
acid synthesis from labeled glucose by adipose tissue explants, 
but inhibited the action of insulin (data not shown). These facts 
suggest that the linkage of the subunits through a disulfied bond(s) 
is essential for manifestation of its action. Table 4 also shows 
that the apo  A-II isolated from human plasma had insulin-stimulating 
activity under our assay conditions. Like H-ISP, apo  A-II itself 
did not have insulin-like activity, but significantly enhanced the 
stimulatory effect of insulin on  14CO2 liberation from labeled 
glucose. These characteristics of H-ISP correspond to those of 
human plasma apo  A-II. 
Effect of H-ISP on lipid synthesis from glucose by isolated rat  
adipocytes  
      As shown in  Table 5, in the presence of both a maximal 
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(2.0 X  10-9 M) and a submaximal (6.7 X  10-11 M) concentration of 
insulin, H-ISP also enhanced total lipid synthesis from labeled 
glucose without influencing basal synthesis (synthesis measured in 
the absence of insulin). 
                              Table 5 
Effect of H-ISP on 2-deoxyglucose uptake by isolated rat adipocytes  
      Next, we examined the effect of H-ISP on 2-deoxyglucose uptake 
by isolated rat adipocytes. Table 6 shows that H-ISP did not change 
the basal rate of 2-deoxyglucose uptake, but significantly poten= 
 tinted the maximal rate of uptake elicited by 1.7 nM insulin. 
                               Table 6 
 B-III. Effect of H-ISP on the binding or degradation of  125I-labeled 
        insulin  by , isolated rat adipocytes  
Effect of H-ISP on specific binding of  125I-labeled insulin to its  
receptor  
        To determine the mechanism of action of H-ISP, we first 
examined its effect on the binding of labeled insulin to specific 
receptors of adipocytes, because enhaced binding of insulin was 
observed with insulin-potentiating fragments of insulin (4,5) and 
growth hormone (6). Results on displacement of labeled insulin 
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    in the presence of unlabeled insulin with or without H-ISP are shown 
    in Fig. 18A. 
                                   Fig. 18A 
    The displacement curve in a range of hormone concentrations of 0.03 
    to 100 nM revealed that H-ISP did not alter the specific binding of 
 125I -labeled insulin to its receptor. Moreover, higher concentration 
    of H-ISP (up to 5 uM) did not increase the specific binding of 125I-
    labeled insulin to adipocyte receptors ( Fig. 18B). It also did not 
    affect nonspecific binding of  125I-labeled insulin (Fig. 18B). 
                                 Fig. 18B 
    Effect of H-ISP on degradation of insulin by isolated rat adipocytes  
          Since prevention of degradation of insulin by adipocytes would 
    result in apparent increase in insulin sensitivity, we next examined 
    the effect of H-ISP on insulin degradation. For this, we measured 
    the trichloroacetic acid precipitability of  125I-labeled insulin in 
    the medium after incubation under the conditions used for the assays 
    described above. Figure 19A shows the time course of insulin degra= 
    dation measured in this way. 
                                 Fig. 19A
    H-ISP had no effect on insulin degradation. Similar results were 
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obtained by radioimmunoassay (Fig. 19B). 
                               Fig. 19B 
B-IV. Effect of H-ISP on pyruvate dehydrogenase activity of isolated  
      rat adipocytes  
Effect of H-ISP on pyruvate dehydrogenase activity of intact adipocytes 
       To examine the action of H-ISP on the representative insulin-
sensitive intracellular enzymes, we next studies its action on mito= 
chondrial pyruvate dehydrogenase. Under the conditions  described 
here, insulin in the range 5 to 200  pU/m1  induced .a small but signi= 
ficant increase in pyruvate dehydrogenase activity, causing maximal 
stimulation at 200  1.1U/m1 (data not shown). As shown in Fig. 20, 
insulin at 200  PU/m1 caused 51.3% increase in the enzyme activity 
over the basal activity, an increase that is comparable to that 
reported by others (62,63). 
                                Fig. 20 
In the same system, H-ISP markedly stimulated the pyruvate dehydro= 
genase activity of intact cells in the absence of added insulin, 
and the magnitude of the activation was greater than that of insulin 
alone. H-ISP at 3  pM caused 193% stimulation of pyruvate dehydro= 
genase activity. Furthermore, as shown in Fig. 20, when cells were 
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incubated with insulin (200  uU/m1) plus H-ISP, the magnitude of 
the activation was  greater than that obtained with insulin or H-ISP 
alone. The stimulatory effect of H-ISP was additive to maximal  stimu= 
lation caused by insulin alone. 
       Figure 21 shows the concentration-response curve for the effect 
of H-ISP upon pyruvate dehydrogenase activity of intact cells. 
                                Fig. 21 
When adipocytes were incubated in the presence of increasing concent= 
rations of H-ISP, the pyruvate dehydrogenase activity increased 
linearly. H-ISP was  effective at over 0.6  uM. 
Effect of H-ISP on pyruvate dehydrogenase activity in subcellular  
systems  
      It has recently been demonstrated (14-16) that a simplified 
subcellular system consisting of plasma membranes and mitochondrial 
fractions from rat adipocytes could be used as a model system for 
studying the action of insulin or insulin mediator and that direct 
addition of insulin or insulin mediator to the mixture caused an 
increase in mitochondrial pyruvate dehydrogenase activity. We next 
examined whether H-ISP had pyruvate dehydrogenase-stimulating 
activity in this subcellular system. As shown in Table 7, the 
addition of H-ISP during preincubation of the plasma  membrane-
mitochondrial mixture in the presence of ATP resulted in stimulation 
of pyruvate dehydrogenase activity by  46.9%. 
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                               Table 7 
In this system, insulin caused  33.3%  (2<0.005) stimulation of 
pyruvate dehydrogenase, which was comparable to the stimulations 
reported by others (64,65). As shown in Table 7 (Experiment 2), 
H-ISP also stimulated pyruvate dehydrogenase activity when added 
to the isolated mitochondrial fraction in the absence of plasma 
memebrane. This is in sharp contrast with the observation that 
the effect of insulin on pyruvate dehydrogenase activity could 
not be produced by treatment of mitochondria alone (64). 
Effect of sodium fluoride on the  stiAmulation of pyruvate dehydro=  
 genase by H-ISP  
      Next we examined the effect of sodium fluoride, a phosphatase 
inhibitor, on the stimulatory effect of H-ISP, since pyruvate 
dehydrogenase activity is known to be increased by activation of 
pyruvate dehydrogenase phosphatase and/or the inhibition of pyruvate 
dehydrogenase kinase (66,67). As shown in Table 8, addition of 
75  mM sodium fluoride to the pyruvate dehydrogenase assay system 
had little effect on the basal activity, but almost completely 
inhibited the stimulatory effect of H-ISP on pyruvate dehydro= 
genase activity. 
                               Table 8 
These results suggest that H-ISP stimulate pyruvate dehydrogenase 
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activity through a sodium fluoride-sensitive mechanism, possibly 
through the pyruvate dehydrogenase phosphatase system. 
B-V. Effect of H-ISP on the phosphorylation of rat adipocyte insulin 
      receptor  
Effect of H-ISP on phosphorylation of the solubilized insulin  
receptor fraction  
      To determine whether the potentiation of insulin-stimulated 
glucose metabolism by H-ISP was correlated with alteration of 
the tyrosine kinase activity of the insulin receptor, we studied 
the effect  of4'11-ISP on the state of phosphorylation of the insulin 
receptor. For this we incubated solubilized rat adipose insulin 
receptors with an equal amount of wheat germ-purified proteins 
and a non-saturating concentration of  [Y-32P]ATP. Figure 22A 
shows autoradiograms of the phosphorylated glycoproteins. The 
major phosphorylated Mr 95,000 protein has been tentatively 
identified as the  a subunit of the insulin receptor of rat 
adipocytes (56, 68). 
                               Fig. 22A 
On incubation of the solubilized fraction with insulin (10 nM), 
the incorporation of 32P into this protein increased approximately 
15-fold, as determined by scanning densitometry (Fig. 22A, lanes 
1 and 3). On incubation with H-ISP (10 pM), the basal and  insulin-
                            _ 
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dependent phosphorylation were both clearly inhibited (Fig. 22A). 
To reduce the background of other proteins and clarify the tyrosine-
specific phosphorylation, we used anti-phosphotyrosine antibodies 
in following experiments. These antibodies were highly specific 
for phosphotyrosine and did not cross-react with phosphoserine or 
phosphothreonine (57). 
     Preincubation of the same receptor fraction with insulin plus 
H-ISP (10 pM) caused  95% decrease in the extent of phosphorylation 
of the Mr 95,000 receptor subunit (Fig. 22B, lanes 7 and 8). 
                               Fig. 22B 
The decrease in autophosphorylation of the  13 subunit of the insulin 
receptor was not attributable to either decreased insulin binding 
or decreased immunoprecipitation, since H-ISP itself did not affect 
insulin binding to adipocyte receptors (Fig. 18) and the inhibition 
was also observed without antibodies (Fig. 22A). 
Effects of the concentrations of H-ISP and insulin on phosphorylation 
of the insulin receptor  
     H-ISP inhibited 10  nM insulin-stimulated autophosphorylation 
of the  a subunit dose-dependently (Fig. 23A), and was inhibitory at 
concentrations of over 0.5  M. 
                               Fig. 23A
     Using the same system, we examined the influence of insulin 
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    concentration on the effect of 10  p.M H-ISP. Insulin caused marked 
    and dose-dependent stimulation of 32P incorporation into the Mr 
    95,000 protien, as observed by Haring et al. using anti-receptor 
    antibodies (56). As shown in Fig. 22B, H-ISP (10  pM) strongly 
    blocked the stimulation of phosphorylation by insulin at the concent= 
    rations tested. 
                                   Fig. 23B 
    Phosphorylation of H-ISP by the solubilized insulin  receptor. 
         Next, we examined whether the inhibitory effect of H-ISP could 
    be because it was a preferable substrate for phosphorylation, since 
    it has eight possible sites per molecule that might be phosphorylated 
    by a tyrosine kinase. However, we could not detected any phosphory= 
    lated H-ISP in two SDS-polyacrylamide gel systems,  NaCl-gel in the 
    absence of 2-mercaptoethanol (Fig. 24B) and 4-18% gradient gel in
    the presence of the reductant (Fig. 24A), though both gel systems
    resolved H-ISP clearly (13). 
                                  Fig. 24A
                                  Fig. 24B
    These results exclude the possibility that H-ISP inhibits auto= 
    phosphorylation of the solubilized receptor fraction by competiting 
    as a substrate for the receptor tyrosine kinase. 
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       Effect of H-ISP on dephosphorylation of insulin receptor  
            Another possibility was that H-ISP might activate phospho= 
       tyrosine phosphatase, thus lowering the extent of phosphorylation 
       of the insulin receptor. To examine this possibility, we stopped 
       the incorporation of 32P into the receptor protein by adding a 
       high concentration of unlabeled ATP and then tested the effect 
       of H-ISP on dephosphorylation. As shown in Fig. 25, H-ISP did 
      not stimulate dephosphorylation of the phosphorylated  IS subunit 
       of the insulin receptor. 
                                      Fig. 25 
       These results strongly suggest that H-ISP inhibited tyrosine-
       specific protein kinase associated with the insulin receptor. 
                                                                                                                                                                                                                                                                                                               • 
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 DISCUSSION 
     This paper describes the presence of an insulin-stimulating 
protein, H-ISP, in human plasma for the first time. 
     H-ISP is composed of two identical subunits connected by a 
single disulfide bond and reduction of this linkage followed by 
carboxymethylation completely abolished its activity. This 
suggests that the disulfide linkage is essential for 
manifestation of the activity. The molecular weight, subunit 
composition, the amino acid composition, and the isoelectric 
point of this protein are comparable with those of human plasma 
apo  A-II. In addition, apo  A-II isolated from human plasma did 
not itself have insulin-like activity, but stimulated the action 
of insulin on CO2 production from glucose in isolated rat 
adipocytes (Table  4). These results support the evidence that 
H-ISP is identical with  huMan plasma apo  A-II. 
     Although the deduced amino acid sequence of this protein was 
found to be identical with that of apo  A-II, our sequence had a 
Glu residue instead of  Gln at position 37. Recently, Sharpe, et 
 al. (69) reported the  nucleotide sequence of the gene encoding 
human plasma apo  A-II and also found a difference at position 37 
in the deduced amino acid sequence. Our sequence is consistent 
with the amino acid sequence deduced from the  nucleotide 
sequence. However, our Cm-H-ISP showed heterogeneity at its C-
terminus, about one-third of the preparation having no  Gln 
residue, as shown in Fig. 8 and Tables 2 and 3. It is not clear 
whether this heterogeneity at the C-terminus is produced during 
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   the purification procedure or whether natural apo  A-II has this 
   heterogeneity. 
        The action of insulin is reported to be modulated by 
   alterations at three levels: before its interaction with its
  receptor, at the level of the receptor, and at steps after 
   insulin-receptor interaction (1,2). Binding of insulin to its 
   receptor is supposed to initiate increase in glucose utilization, 
  the first and most rate-limiting step in this process being the 
  rate of glucose transport. We found that H-ISP enhanced the 
  action of insulin on glucose transport without modifying insulin-
  receptor binding. It also did not affect the rate of 
  degradation of insulin by adipocytes. Thus H-ISP may modulate 
  the action of insulin at a step after insulin-receptor 
   interaction. 
        Change in insulin-receptor binding is thought to be 
  associated with alteration of insulin sensitivity, whereas change 
  at post-receptor levels is thought to result in alterations in 
   insulin responsiveness (1,2). There are reports that insulin 
  fragments (4,5) or fragments from human growth hormone (6) change 
  the sensitivity of adipose tissue to insulin and potentiate the 
  action of insulin in vitro. These fragments are thought to 
  enhance the action of insulin by increasing the binding of 
  insulin to the insulin receptor, since they enhance its specific 
  binding to its receptor. On the other hand, insulin sensitivity 
  may be altered without any change in insulin binding. For 
   instance, ATP-deficiency results in decreased insulin sensitivity 
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due to a post-receptor defect in rat adipocytes (70), and 
conversely adenosine potentiates the action of insulin by 
increasing the sensitivity of adipocytes to insulin, without 
affecting insulin binding (71). As shown in the present study 
H-ISP had no affect on insulin-receptor binding (Fig. 18), but 
shifted the concentration -response curve of insulin-dependent 
fatty acid synthesis by adipose tissue preparations to the left 
(Fig.  16). In addition, it increased both the sensitivity and 
responsiveness to insulin, as assessed by CO2 production from 
glucose (Fig. 17) and uptake of 2-deoxyglucose (Table 6) by rat 
adipocytes. These results suggest that the mechanism of action 
of H-ISP is closely related to that of adenosine. However, at 
higher concentrations, adenosine exhibits an insulin-like action 
in stimulating 2-deoxyglucose uptake (71) and also pyruvate 
dehydrogenase activity (72) in adipocytes, and its mechanism of 
action is suggested to be in some way similar or related to that 
of insulin (72). 
 In the present study, we demonstrated that H-ISP had an 
insulin mediator activity and thus that it caused dose-dependent 
stimulation of the activity of mitochondrial pyruvate 
dehydrogenase in intact adipocytes and also in the plasma 
 membrane/mitochondria mixture in the absence of added 
 insulin(Fig. 21 and Table 7  ). Furthermore, the effect of H-
ISP on pyruvate dehydrogenase activity could be produced by 
treatment of the isolated mitochondrial fraction alone (Table 7, 
experiment  2). 
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     Pyruvate dehydrogenase is known to be regulated by a 
phosphorylation-dephosphorylation mechanism: phosphorylation of 
the  a subunit of the enzyme and concomitant inactivation is 
catalyzed by a  CAMP-independent protein kinase, and 
dephosphorylation and  concomitant reactivation by a 
phosphoprotein phosphatase, pyruvate dehydrogenase phosphatase 
(66,67). As shown in the present paper(Table 8), the action of 
H-ISP on pyruvate dehydrogenase was almost  completely abolished 
by sodium fluoride, a phosphatase inhibitor, suggesting that H-
ISP stimulates pyruvate dehydrogenase activity by activating 
pyruvate dehydrogenase phosphatase. In this connection, it is 
noteworthy that insulin mdiator was shown to activate 
mitochondrial pyruvate dehydrogenase in the absence or presence 
of ATP and its activation was also found to be inhibited by 
sodium fluoride, but not by the kinase inhibitor dichloroacetic 
acid (14-16,73). Newman et al. (74) showed that insulin 
mediator behaved as an activator of pyruvate dehydrogenase 
phosphatase, but had no effect on pyruvate dehydrogenase kinase 
activity. These findings are consistent with the view that H-
ISP activates pyruvate dehydrogenase through a similar mechanism 
to that of insulin mediator. Further studies on the mechanism 
of pyruvate dehydrogenase activation by H-ISP are in progress. 
     Using rat adipocytes. Jarett et al. (62) showed that insulin 
induces production of a limited amount of the mediator per cell 
in a dose-dependent manner, that the amount determines the 
magnitude of stimulation of pyruvate dehydrogenase by insulin and 
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 that this stimulation can be further enhanced by the presence of 
 more mediator. As described in this paper, insulin caused a 
 maximum stimulation of pyruvate dehydrogenase activity of about 
 50 % in adipocytes (Fig. 20), this value being comparable to 
 those reported by others (62,63). On the other hand, H-ISP 
 enhanced the enzyme activity approximately 3-fold (Fig. 21) and 
 this enhancement was additive to the maximum stimulation obtained 
 with insulin alone. These results also support the similarity 
 of the mechanisms of pyruvate dehydrogenase activation by insulin 
 mediator and by H-ISP. 
       As reported in this paper, H-ISP stimulate 2-deoxyglucose 
 uptake, glucose oxidation and fatty acid synthesis, both in 
 adipose explants and adipocytes in the presence of suboptimal 
 concentrations of insulin. Since pyruvate dehydrogenase is one 
 of the major rate-limiting enzymes in the pathway of fatty acid 
  synthesis, it can be inferred that changes in its activity could 
  mediate the short-term metabolic effects of insulin. However, 
  Begum et al. (63) suggested from experiments using indomethacin 
  that pyruvate dehydrogenase is not the rate-limiting step in 
  glucose oxidation in fat cells. Therefore, the insulin-
  stimulating activity of H-ISP cannot be simply explained by 
  activation of pyruvate dehydrogenase. Besides pyruvate
  dehydrogenase, some other insulin-sensitive enzymes related to 
  glucose utilization are also known to be controlled by a 
  phosphorylation-dephosphorylation mechanism and activated by 
  dephosphorylation. These include glycogen synthase (18), 
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pyruvate kinase (75) and acetyl-CoA carboxylase (19), but little 
is known about the other key enzymes. If a phosphorylation-
dephosphorylation control like that of pyruvate dehydrogenase is 
applicable to these key enzymes, an increase in glucose 
utilization by H-ISP would be expected in the presence of added 
insulin. Since H-ISP has little effect on glucose metabolism on 
adipocytes in the absence of insulin, it is likely that a glucose 
transport system is controlled by a different mechanism from that 
mentioned above. 
     In the present study, we showed  that H-ISP inhibits 
tyrosine-specific protein kinase associated with the insulin 
receptor. The biological significance of the present results is 
not clear. It has been proposed that phosphorylation of the 
8 subunit of the insulin receptor by the receptor tyrosine kinase 
may represent an intermediary step in the actions of insulin on 
metabolism and growth (1,76). In this connection, Kono and 
Barham (77) showed that trypsin causes similar stimulation to 
insulin of glucose oxidation in rat adipocytes.  Larner et al. 
(78) reported that TLCK, an inhibitor of trypsin-like proteases, 
markedly inhibited glucose oxidation but not  insulinzbinding in 
rat adipocytes. On the other hand, Tamura et al. (79) 
demonstrated the stimulation by trypsin of phosphorylation of the 
13 subunit of the insulin receptor. As shown in Table 9, TLCK 
and leupeptin, a potent inhibitor of both serine proteases and 
thiol proteases with trypsin-like specificity, inhibited glucose 
oxidation in rat adipocytes 83 % and 51 %, respectively, 
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(Experiment 1) and they also blocked insulin-dependent 
phosphorylation to similar extents (Experiment 2). 
                              Table 9 
These data support the idea that activation of the receptor-
associated tyrosine kinase is one of the integrated events in the 
action of insulin. Thus H-ISP may inhibit the phosphorylation 
through a feedback mechanism, since it potentiates the action of 
insulin and acts as an insulin mediator in the activation of 
pyruvate dehydrogenase both in intact adipocytes and in 
mitochondrial fractions in the absence of added insulin (Fig . 21 
and Table 7). Further studies on the detailed mechanism of H-
ISP action are now in progress. 
     Recently,  Arner et al. (10) reported that glucose ingestion 
was accompanied by a marked increase in insulin sensitivity of 
human fat cells and they suggested that oral glucose stimulates 
the release of a circulatory factor(s) that  potentiates the 
insulin effect. Livingston et al. (11) also observed an 
 increase in insulin sensitivity of rat adipocytes after
intravenous glucose infusion. However, little is known about 
the cellular processes that could enhance insulin sensitivity. 
Therefore, it might be of interest to examine the participation 
of H-ISP in these processes and also at the clinical level to 
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investigate the relationship between H-ISP and the etiology of 
non-insulin-dependent diabetes mellitus. 
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Table 1. Amino acid composition ofH-ISP 
Values for H-ISP were calculated from average values for samples of 
24-h, 48-h and 72-h hydrolyzates. The nearest integer values are shown 
in parentheses. Values for apo  A-II are cited from  (60).  '/2 Cys was 
determined as S-carboxymetylcysteine 
Amino acid Residues/molecule in 
         H-ISP Apo  A-II 
 Asp 6.17 (6) 6 
Thr 12.09 (12) 12 
Ser  11.97  .(12) 12 
Glu 32.19 (32) 32 
Pro 8.18 (8) 8 
Gly 6.42 (6) 6 
Ala  10.10 (10) 10 
Val 12.03 (12) 12 
1/2 Cys 2.17 (2) 2 
Met 1.57 (2) 2 
 Ile 1.84 (2) 2 
Leu 16 (16) 16 
Tyr  7.94 (8) 8 
Phe 7.89 (8) 8 
Trp 0.00 (0) 0 
Lys 17.86 (18) 18 
His 0.00 (0) 0 
Arg 0.00 (0) 0 
Total 154 154 
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 Table 2. Amino  acid  compositions  and  other  data  on  tryptic  peptides  of  Cm-H-ISP 
 Tryptic  peptides  were  separated by  ['PLC.  1"-n correspond topeak fractions in  Fig.  g. Numbers  of  amino acid  residues  inparentheses  indicate 
nearest integer values. Mass values without and with parentheses indicate observed mass values in  Fig.  9  and theoretical mass values calculated 
from the amino acid compositions, respectively. Underlined values coincide with observed values 
       T-1 T-2 T-3 T-4 T-5 T-6 T-7  T-8 T-9 T-10 
                                T-2A  T-2B 
 GMC-Cys 1.02 (1) 
 Asp 1 (1) 1.03 (1) 0.98 (1) 1.06 (1) 0.89 (1) 0.89 (1) 
  Thr 0.99  (1) 1.03 (1) 1.88 (2) 2.96 (3) 2.95 (3) 3.18 (3) 3.12 (3) 
   Ser 0.98 (1) 0.22 (1) 1.00 (1) 1.03 (1) 1.90 (2) 0.96 (1)  1.03 (1) 0.85 (1) 0.90  (I) 
 Glu 3.00 (3) 1.55 (1) (3) 1.05  (1) 2.12 (2) 2.13 (2) 4.05 (4) 4.03 (4) 3.23 (3) 4 (4) 3 (3) 
 Gly 1.11 (1) 2.25 (2) 2.35 (2) 2.38 (2) 2.37 (2) 
 Ala 2 (2) 0.35 (2) 2 (2) 2 (2) 2.85 (2) 2.52 (2) 
 Val 0.13 (1) 2.95 (3) 1.77 (2) 1.81 (2) 1.58 (2) 1.59 (2) 
 Met 0.82 (1) 
  Leu 0.99 (1)  1.15(1) (1) 2 (2) 2 (2) 1 (1) 2.72 (3) 2.61 (3) 2.52 (3) 2.46 (3) 
 Ile 0.82 (1) 0.86 (1) 
  Tyr 1.00 (1) 2.06 (2) 1.00 (1) 1.03 (1) 0.90 (1) 0.94  (1) 
 Phe 1 (1) 1.01 (1) 1.75 (2) 1.81 (2) 1.60 (2) 1.62 (2) 
   Lye 1.01 (1) 1.29 (1) (2) 1.01 (1) 1.87 (2) 0.88 (1) 1.04 (1) 1.00 (1) 0.97 (1) 
   Pro 0.80 (1) 0.12  (1) 0.90 (1)  0.874.(1) 1.03 (1) 0.94 (1) 0.80 (1) 1.08 (1) 1.00  (1) 
 Recovery 5.68 5.60 5.60 3.06 2.39 3.76 0.84 0.51 1.49 0.74 
  (nmol) 
 (11+111+ 972.6 635.4 1199.6 673.2 1156.7 941.5 2351.2 2513.6 2385.3 2385.3 2257.1 
               (970.5) (633.3)(1197.7) (672.3) (1155.7) (940.6) (2348.1) (2511.3) (2383.3) (2383.3) (2255.2)                (971
.5)  (634.3)(1198.7) (673.3) (1156.7) (941.6) (2349.1) (2512.3) (2384.3) (2384.3) (2256.2) 
               (972.5) (635.3)(1199.7) (1157.7)  (942.6) (2350.1) (2513.3) (2385.2) (2385.2) (2257.1)           (973
.5) (1200.6) (2351.1) (2514.3) (2386.2) (2386.2) (2258.1) 
                                                                 (2352.1) (2515.3) (2387.2) (2387.2) (2259.1)                                                          
, (2353.0) (2516.2) (2388.1) 
  Total amino      9 5 11 5 10 
8 20 23 22 22 21    acid residues 
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Table 3. Amino acid compositions and  other data on protease V8 peptides of  Cm-H-ISP 
Protease V8 peptides were separated by  H  PLC. V-n denote peak fractions in  Fig,10. Numbers of amino acid residues in parentheses indicate 
nearest integer values. Mass values without and with parentheses indicate observed mass values in  Fig.  nand theoretical mass values calculated 
from the amino acid compositions, respectively. The theoretical values coinciding with observed values are underlinded 
 V-1 V-2 V-3 V-4 V-5 V-6 V-7 V-8 V-9 
  CMC-Cys 1.02 (1) 
 Asp 2.02 (2) 1.17 (1) 
     Thr 1.83 (2) 2.06 (2) 1.99 (2) 1.88 (2) 
    Ser 1.22 (1) 0.94 (1) 1.86(2) 1.16 (1) 
 Glu 1.95 (2)  1.34 (1) 1.89 (2) 1.12 (1) 2.96 (3) 1.07 (1) 2.03 (2) 3.09 (3) 1.16 (1) 
 Gly 0.99  (I)  1.15 (1) 1.01 (1) 1.09 (1) 
     Ala 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 
    Val 1 (1) 0.93  (1) 2.03 (2) 1.99 (2) 
 Met 0.91 (1) 
      Leu 0.95 (1) 0.95 (1) 1.03  (1)•  , 1.94 (2) 2 (2) 2 (2) 
 Ile 0.80 (1) 
   Tyr 1.02 (1) 2.04 (2) 1.10 (1) 
   Phe 0.95 (1) 1.01 (1) 2.01(2) 
 Lye 2.72 (2) 0.99 (1) 1.05  (1) 1.83 (2) 1.00 (1) 
       Pro 1.16 (1) 0.83 (1) 0.92 (1) 0.77  (1) 0.79  (1) 
           Recovery            5.76 4.05 3.73 1.86 5.56 5.42 4.11 3.81 1.15  (nmol) 
 [M+Hi+  460.3' 687.6 815.6 687.6 944.7 744.6 1298.9 2224.4 1230.9 
                   (459.3) (686.4) (815.4) (687.4) (959.5)  (743.4) (1297.8) (2221.1) (1229.7)
                   (460.2) (687.4)  (816.4) (688.4) (960.4) (744.4) (1298.8) (2222.1) (1230.6) 
             (461.2) (817.4) (964.4)  (1299.8) (2223.1) (1231.6) 
                             (962.4) (2224.0) 
                                                                                         (2225.0) 
                                                                                         (2226.0) 
          Total  amino     4 6 8 7 8 6 12 19 10 
          acid  residues 
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Table 4. Effect of Cm-H-ISP and apo  A-II on CO2 liberation from 
glucose by isolated rat adipocytes 
Experimental conditions were as described in the text. Total values 
are given as means  + SEM (n = 4), except hose of experiments 
with Cm-H-ISP which are means for duplicate determinations in two 
separate xperiments. For insulin-stimulated values, P (vs. respective 
control activity) was calculated by the paired t test 
Addition Insulin  14CO2 liberated from  D-[1-14C]glucose 
   (30  gU/m1)   
                     total insulin-stimulated 
                     nmol  h-1/106 cells
None 9.59  ± 0.37 
 49.97  +1.03 40.38  (P  <  0.005) 
H-ISP 9.88  + 0.54 
 (1.2  gM) + 64.61  ±1.40 54.73 (P < 0.01) 
 Apo-A-II. 9.76  + 0.18 
 (1.2  gM) + 60.13  ± 1.50 50.37 (P < 0.001) 
 Cm-H-ISP — 8.63 
 (2.4  gM) + 8.94 
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Table 5. Effect of H-ISP on lipid synthesis from glucose by isolated adipocytes . 
Experimental conditions were described in the text. Values are means ± SEM for 
three separate experiments. 
Insulin H-ISP Total lipid synthesized from  D-[U-14C]glucose 
 (M) (1.2  pM)  (
nmol/106 cells/h) 
                                            Total                                                                        Insulin-
                                                                         stimulated 
0 15.0 ± 1.8 
                                           14.8 ± 1.6
6.7 X  10-11                         21.2 ± 1.6 7.2 ± 0.3 
                          25.3 ± 1.5 10.5 ±  0.3a
2.0 X  10-9                           42.4 ± 2 .7 27.4 ± 1.7 
                          49.0 ± 2.7 34.2 ± 1.4b
 a
p<0.005,  bp<0.02 (vs. respective value without H-ISP) by the paired t test. 
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Table 6. Effect of H-ISP on  2-deoxyglucose uptake by isolated rat 
adipocytes 
H-ISP, 1.2 p.M. Values are means  + SEM (n = 5) 
Insulin H-ISP  2-Deoxyglucose uptake 
                  total insulin-stimulated 
                     nmol  min-1/106  cell.
0 0.81  + 0.05 
 0.76  +  0.07 
 1.7  nM —  4.87  +  0.41  4.06  +  0.36 
 5.87  +  0.47 5.11  ±0.448 
    P < 0.05 (vs value without H-ISP) by paired-data analysis. 
 64
         Table 7. Stimulation of pyruvate  dehydrogenase activity by insulin or 
         H-ISP in subcellular systems 
        In experiment 1, the mixture of plasma membrane (200  µg/ml) and 
 mitochondria (500  µg/ml) was incubated for 10  min with ATP 
        (250  RM); in experiment 2, the mitochondria (500  µg/ml) weresub-
         stituted for the plasma membrane/mitochondria mixture. Then pyru-
         vate dehydrogenase activity was assayed for 3  min as describedinthe
         text. Values are means  ± SEM  (ii = 4). P values were calculated
        (vs. respective control activity) by the paired  t test 
       Expt Addition  Pyruvate Stimulation 
                              dehydrogenase 
                            activity 
                            nmol(mgmito
 protein)-1 
       1. Control 4.48  ± 0.08 
              Insulin 
             (200  RU/m1) 5.97  ± 0.18 33.3 (P < 0.005) 
              H-ISP 
              (2.0  1.1M) 6.58  ± 0.20 46.9 (P < 0.001) 
       2. Control 3.65  ± 0.09 
              H-ISP 
              (2.0  RM) 5.15  ± 0.21 41.1 (P < 0.002) 
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  Table 8. Effect of sodium fluoride on the stimulation  of  pyruvate  dehy-
  drogenase by  11-ISP 
 The mixture of plasma membrane (200  pig/m1) and mitochondria 
 (500  pg/m1) was preincubated for 10  min at  37°C with ATP (250  gM) 
 and with or without sodium fluoride (75 mM). Then pyruvate dehy-
 drogenase activity was assayed for 3  min as described in the text. 
 Values are means  ± SEM  (ii = 4) 
 Expt Pyruvate dehydrogenase activity 
            no NaF 75mM NaF 
 nmol (mg  mito 
 protein)'  min-1 
 Control 4.47  ± 0.06 4.24  ± 0.15 
 H-ISP (2.0  AM) 6.64  ± 0.44 4.58  ±0.38 
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Table 9. Effects of TLCK or leupeptin on glucose oxidation and insulin receptor phosphorylation 
Inhibitor Experiment 1 Experiment 2 
                         Insulin-stimulateda 
             Insulin  14002 liberation from Inhibition Insulin Phosphorylation b Inhibition 
           (0.2 nM) D-[1-14C]glucose  (%) (10 nM) (arbitrary units)  (%) 
 (nmol/106 cells/h) 
None + 34.66 + 36.5 
TLCK  + 5.84  (a<0.001) 83.2 + 7.8 78.6 
 (250  uM) 
Leupeptin + 16.94  (2.<0.001) 51.1 + 17.3 52.6 
 (50  pg/m1) 
 a 
  Values are means of those obtained with 4 rats. 
b   Val
ues are means of two separate experiments. 
 In Experiment 1, adipocytes were incubated at 37°C for 2 h with or without insulin (0.2  nM) in the presence 
 or absence of TLCK or leupeptin. The values without insulin were 6.70 ± 0.13 (none), 6.30 ± 0.31 (TLCK) 
and 6.86 ± 0.27 (leupeptin) nmol  14CO2/106 cells/h, respectively. For insulin-stimulated values,  £(vs . 
                                                                                  c value with insulin alone) was calculated by the paired t test. In  Experiment 2,  phosphorylation was 
assayed as described in the text. The autoradiograms were scanned  with .a  Joyce-Loebl microdensitometer 
and the peak areas corresponding to the Mr 95,000 band were calculated and expressed in arbitrary units . 
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Fig. 1. Purification of H-ISP from human plasma. 
    Human plasma  (1 liter) 
         chilled ethanol (2 liters) was added and the mixture was 
         stirred for 30  min in the cold 
         centrifuged at 10,000 X g for 30  min 
    Supernatant 
          concentrated at 37°C under reduced pressure 
    Concentrated supernatant 
          shaken with an equal volume of chloroform 
    Aqueous phase 
          concentrated at 37°C under reduced pressure,  dialyzed and 
         lyophilized 
      V 
    Dried material 
         dissolved in 10  mM Tris-HC1 buffer (pH 7.4) containing 
         0.1  M  NaCl 
      V 
    Sephadex  G-100 column chromatography 
 eluted with the  same buffer and fractions containing H-ISP 
         activity were pooled, dialyzed and lyophilized 
      V 
    Reversed-phase HPLC (TSK gel ODS-120A, Toyo Soda) 
         active fractions were pooled and lyophilized 
    Reversed-phase HPLC (Hi-Pore  RP-304f Bio-Rad) 
         active fractions were pooled and lyophilized 
    H-ISP 
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Fig.  2. Sephadex  G-100 column chromatography. The fractions pooled for 
subsequent purification are indicated by a horizontal bar.
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Fig. 3
70
Fig. 3. Reversed-phase HPLC on a TSK gel ODS-120A column. 
The horizontal bar indicates the fractions of H-ISP pooled.
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Fig. 4. HPLC of H-ISP on a Hi-Pore RP-304 column. The horizontal 
bar indicates the fractions of H-ISP pooled and used for further 
experiments.
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Fig. 5. SDS-polyacrylamide gel electrophoresis of purified H-ISP. 
Purified H-ISP (10  pg.) was boiled for 3  min in  Laemmli's sample 
buffer (41) in the absence (lane 1) or presence (lane 2) of 5%  2- 
mercaptoethanol. For other conditions, see text.
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Fig. 6. Gel filtration chromatography of H-ISP and Cm-H-ISP on 
Sephadex G-75 in 6 M guanidine hydrochloride. Approximately 1 mg 
of each protein was dissolved in 1 ml of 6  M guanidine hydrochloride 
and loaded on a Sephadex G-75 column (1.0 X 180 cm). Materials were 
eluted with 6  M guanidine hydrochloride at a flow rate of 10  ml/h 
and fractions of 1 ml were collected. Elution patterns of H-ISP 
 (-41—) and Cm-H-ISP  (-0-1 are indicated. The molecular weight 
standards used were:  myoglobin (Myo., 17,000), oxidized bovine pan= 
creatic ribonuclease A (RNaseA, 13,500), lima bean trypsin inhibitor 
(T.Inh., 8,400), and bovine pancreatic insulin (Ins., 5,700). The 
positions of the standard proteins eluted are indicated.
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 Fig. 7. Isoelectric gel focusing of H-ISP and apo  A-II. Samples 
(50 pg) were subjected to isoelectric gel focusing as described in 
the text. For estimation of  pI values, the gel was sliced into 5 mm 
segments and each segment was extracted with 1 ml of water. Gels 
were stained with Coomassie brilliant blue R-250.
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Fig. 8. HPLC profile of the tryptic digest of Cm-H-ISP. 
Chromatographic conditions were as described in the text.
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Fig. 9
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Fig. 9. FAB mass spectrum of the tryptic digest of Cm-H-ISP.
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Fig. 10. HPLC profile of the protease V8 digest of Cm-H-ISP.
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Fig. 11
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Fig. 11. FAB mass spectrum of the protease V8 digest of Cm-H-ISP.
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Fig. 12. FAB mass spectrum of: (A)  V-5 and (B) the digest of 
V-5 with pyrrolidonecarboxylate peptidase.
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 Fig. 13 
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Fig. 13. Partial amino acid sequence of Cm-H-ISP searched by the 
computer program and its comparison with that of human apo  A-II 
(60). Arrows indicate residues determined by a combination of 
CPase Y  (-s--) or aminopeptidase M  (--7) or pyrrolidonecarboxylate 
peptidase  (-->) digestion and FAB mass spectrometry. 
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Fig. 14. FAB mass spectrum of the CPase Y digest of T-2 in Fig. 8.
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Fig. 15. Effects of insulin and H-ISP on the time course of fatty 
acid synthesis by explants of adipose tissue. Incubations were 
carried out as described in the text. Values are means for tri= 
plicate determinations.  C), without insulin;  40, insulin (20  mU/mi); 
   , insulin (0.2  mU/m1);  X, insulin  (0.2  mU/m1) plus H-ISP (20 pg/ 
ml);  ^tH-ISP alone (20  pg/mi).
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Fig. 16
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Fig. 16. (A) Effect of the concentration of H-ISP on fatty acid 
synthesis from glucose in the presence of insulin. Adipose tissue 
explants were incubated at 37°C for 20 h with the indicated concent= 
rations of H-ISP in the absence (0) or presence  (40) of insulin 
(0.2  mU/m1). Values are means for duplicate determinations in two 
separate experiments. (B) Dose-response curves for the effects of 
insulin with and without H-ISP. Adipose tissue explants were incu= 
bated with the indicated concentrations of insulin alone  (0) or 
with H-ISP (15  pg/ml)  (40). Values are means for duplicate determi= 
nations in two separate experiments.
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Fig. 17
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Fig. 17. A, Effect of H-ISP on glucose oxidation in the absence 
and presence of insulin. Cells were incubated at 37°C for 2 h in 
medium containing 0.2  mM D-[1-14C]glucose (0.3  pCi) with the indicated 
concentrations of H-ISP without (0) or with  (40) 67 pM insulin. 
Values are means for duplicate determinations in two separate 
experiments. B, Concentration-response curve for the effect of 
insulin on glucose oxidation with and without H-ISP. Cells were 
incubated with the indicated concentrations of insulin alone  (0), 
or with H-ISP (1.2 pM)  (40). Data are means ± SEM for duplicate 
determinations in four separate experiments. *1 2 < 0.01; **, 
  < 0.002 (for difference from value with insulin alone) .
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Fig. 18
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Fig. 18. A, Displacement of 125I-labeled insulin by unlabeled 
insulin. Cells were preincubated at 37°C for 1 h without (0) or 
with  (40) 1.2 pM H-ISP, and 125I-labeled insulin binding to adipo= 
cytes was determined as described in the text. Values are corrected 
for nonspecific binding. B, Effect of H-ISP on 125I-labeled insulin 
binding to adipocytes. Cells were preincubated with the indicated 
concentrations of H-ISP at 37°C for 1 h  and  then incubated at 37°C 
for 30  min with 125I-labeled insulin (70  pM) in the absence  (40) 
and presence (0) of cold native insulin (58  pg/m1). Values are 
means for triplicate determinations.
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Fig. 19
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Fig. 19. Effect of H-ISP  on degradation of insulin by adipocytes. 
A, Cells (7 X  105  cells/ml) were incubated at 37°C for the indicated 
times without (0) or with  (40) 1.2  pM H-ISP in the presence of  125I_ 
labeledinsulin (70  pM) plus native insulin (130 pM). Then tri= 
chloroacetic acid-presipitable  125I activity in the medium was 
measured. Results are plotted as percentages of values for 125I-
labeled insulin in the medium before the addition of cells against 
time. B, Cells (7 X  105  cells/ml) were incubated at 37°C for the 
indicated times without (0) or with  (40) 1.2  11M H-ISP in the 
presence of cold insulin (37  pU/m1). The content of insulin in the 
medium was determined by  radioimmunoassay as described in the text . 
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Fig. 20. Effects of insulin and H-ISP on pyruvate dehydrogenase 
activity of intact adipocytes. Adipocytes (7-9 X  105cells/ml) 
 were incubated for 15  min at 37°C in Krebs-Ringer phosphate buffer 
containing 10  mM  NaHCO3, 10  mM Hepes, 0.2  mM glucose and 10  mg/ml 
of bovine serum albumin with H-ISP (3  pM) in the presence or absence 
of insulin (200  0/m1). The cell layer was washed and extracted and 
pyruvate dehydrogenase activity was assayed for 3  min as described 
in the text. Values are means ± SEM (n=4).  *, 2 < 0 .005, 
**, 2 < 0 .001 (vs. respective control activity) by paired t test .
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Fig. 21. Effects of various concentrations H-ISP on pyruvate 
dehydrogenase activity of intact adipocytes . Adipocytes (7-9 X  105 
 cells/ml) were incubated for 15  min at 37°C with the indicated 
concentrations of H-ISP as described in Fig . 20. Then pyruvate 
dehydrogenase activity was assayed for 3  min as described in the 
text. Values are means ± SEM (n=4).
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Fig. 22. Effect of H-ISP on phosphorylation of the solubilized 
insulin receptor fraction. Insulin receptor purified on wheat 
germ agglutinin as described in the text was preincubated with 
or without 10 nMinsulin in the presence or absence of 10 pM H-ISP 
                                                                  at 25°C for 1 h. Phosphorylation was assayed as described in the
text using 8.5 lig protein and 0.1 mCi [1-32P]ATP per lane. 
For (B), samples were treated with anti-phosphotyrosine antibodies. 
Lanes 1 and 5, no addition; lanes 2 and 6, H-ISP (10 pM); lanes 3 
and 7, insulin (10 nM); lanes 4 and 8, insulin (10 nM) and H-ISP 
(10  11M).
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Fig. 23. Effects of the concentrations of H-ISP and insulin on 
phosphorylation of the insulin receptor. (A) Effect of H-ISP 
concentration. Samples of receptor fraction (8.5  pg) were pre= 
incubated with (lanes 2-5) or without (lane 1) 10 nM insulin in the 
presence of increasing concentrations of H-ISP at 25°C for 1 h. 
Phosphorylation, immunoprecipitation, SDS-polyacrylamide  (7 .5%) 
gel electrophoresis, and autoradiography were performed as described 
in the text. (B) Effect of insulin concentration. After pre= 
incubation for 1 h with the indicated concentrations of insulin 
in the absence (lanes 1,3,5 and 7) or presence (lanes 2 ,4,6 and 8) 
of H-ISP (10 pM), the solubilized insulin receptor (8 .5 pg) was 
incubated for 1 h with 5 pM  [y-32P]ATP, 2 mM MnC1
2, and 10  mM MgC12. 
Other experimental conditions were as described in the text .
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Fig. 24. Phosphorylation of H-ISP by the solubilized insulin 
receptor. Samples of receptor fraction (8.5 pg) were preincubated 
with 10  nM insulin in the presence (1) or absence (2) of 10  all H-ISP. 
Then, the phosphorylated and immunoprecipitated proteins were 
analyzed in one of the two following systems:  A), a linear gradient 
of 4-18% acrylamide (acrylamide : bis-acrylamide=20 : 1); B), 20.9% 
acrylamide containing a trace amount of  NaCl. Arrows indicate 
bands of H-ISP.
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Fig. 25. Effect of H-ISP on dephosphorylation of insulin receptor. 
The receptor fractions (9  lig) were incubated without (lane 1) or 
with (lanes 2 to 6) insulin (100 nM) at 25°C for 1 h, and then 
incubated with  [y-32F]ATP (5  uM, 160 pCi/nmol),  MnC12 (2 mM), and 
MgC12 (10 mM) for 15  min at 4°C. ATP was then added to a final 
concentration of 1 mM with (lanes 4 and 6) or without  -(lanes 1,2,3 
and 5) H-ISP (10  4M) and the samples were incubated for 0 min(lanes 
1 and 2), 15  min (lanes 3 and 4), or 60  min (lanes 5 and 6) at 4°C. 
The reaction was stopped as described in the text.
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